Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27081
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Balasubramanian, Adithya | - |
dc.contributor.author | Qu, Liang G | - |
dc.contributor.author | Weickhardt, Andrew J | - |
dc.contributor.author | Bolton, Damien M | - |
dc.contributor.author | Perera, Marlon | - |
dc.date.accessioned | 2021-07-26T05:07:03Z | - |
dc.date.available | 2021-07-26T05:07:03Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.citation | Internal Medicine Journal 2021; 51(7): 1173-1177 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/27081 | - |
dc.description.abstract | The availability of efficacious systemic therapies for metastatic clear cell renal cell carcinoma has heralded improved survival for Australians. The Pharmaceutical Benefits Schedule registry was interrogated to assess nation-wide prescribing patterns. Sunitinib remained the most commonly prescribed agent. Prescribing rates were significantly lower in Northern Territory than in other states, raising questions of disparities in access to care. | en |
dc.language.iso | eng | |
dc.subject | immunotherapy | en |
dc.subject | metastatic | en |
dc.subject | oncology | en |
dc.subject | renal cell cancer | en |
dc.subject | systemic therapies | en |
dc.subject | tyrosine kinase inhibitors | en |
dc.title | Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (mRCC) in Australia. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Internal Medicine Journal | en |
dc.identifier.affiliation | Olivia Newton-John Cancer Wellness and Research Centre | en |
dc.identifier.affiliation | Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Surgery (University of Melbourne) | en |
dc.identifier.affiliation | Department of Urology, Western Health, University of Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Austin Health | en |
dc.identifier.doi | 10.1111/imj.15419 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-1138-6389 | en |
dc.identifier.pubmedid | 34278692 | |
local.name.researcher | Balasubramanian, Adithya | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Urology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.